We are live on ! Find out more
BL

Bleichroeder LP Portfolio holdings

AUM $559M Turnover 17.24%
1-Year Est. Return 83.7%
This Fund
S&P 500
This Quarter Est. Return
+8.56%
1 Year Est. Return
+83.7%
3 Year Est. Return
+202.15%
5 Year Est. Return
+208.71%
10 Year Est. Return
–
AUM
$559M
AUM Growth
-$19.6M
Cap. Flow
+$14.4M
Cap. Flow %
2.58%
Top 10 Hldgs %
77.52%
Holding
87
New
6
Increased
9
Reduced
8
Closed
9
Avg Time Held
2.7 years
Top 10 Avg Time Held
2.3 years
Top 20 Avg Time Held
2.5 years

Top Buys

Rank Stock Value
1
LIQT icon
LiqTech
LIQT
+$5.92M
2
COGT icon
Cogent Biosciences
COGT
+$3.5M
3
CUE icon
Cue Biopharma
CUE
+$3.24M
4
SPIR icon
Spire Global
SPIR
+$2.51M
5
DTIL icon
Precision BioSciences
DTIL
+$2.5M

Top Sells

Rank Stock Value
1
LIN icon
Linde
LIN
+$4.07M
2
JPM icon
JPMorgan Chase
JPM
+$1.49M
3
POCI icon
Precision Optics
POCI
+$1.19M
4
RTX icon
RTX Corp
RTX
+$1.16M
5
FLNT icon
Fluent
FLNT
+$831K

Sector Composition

Rank Sector Weight
1 Miscellaneous 41.42%
2 Industrials 22.38%
3 Healthcare 17.16%
4 Technology 6.03%
5 Materials 5.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GLD icon
1
SPDR Gold Trust
GLD
$139B
$175M 31.31%
475,000
– –
2019 Q4
26 quarters
GPGI icon
2
GPGI Inc
GPGI
$3.61B
$63M 11.26%
3,972,176
+2,500
+0.1% +$35.8K
2022 Q1
17 quarters
SPY icon
3
State Street SPDR S&P 500 ETF Trust
SPY
$813B
$50.5M 9.04%
67,645
– –
2023 Q4
10 quarters
RHLD icon
4
Resolute Holdings Management
RHLD
$884M
$45.4M 8.12%
314,166
– –
2025 Q1
5 quarters
LIN icon
5
Linde
LIN
$227B
$31.4M 5.61%
60,434
-8,040
-12% -$4.07M
2019 Q4
26 quarters
DUOT icon
6
Duos Technologies
DUOT
$176M
$19.5M 3.49%
1,627,806
– –
2020 Q1
25 quarters
DTIL icon
7
Precision BioSciences
DTIL
$166M
$15.9M 2.84%
2,018,190
+355,690
+21% +$2.5M
2025 Q1
5 quarters
CUE icon
8
Cue Biopharma
CUE
$135M
$11.7M 2.09%
370,682
+143,377
+63% +$3.24M
2019 Q4
26 quarters
BX icon
9
Blackstone
BX
$84.8B
$10.7M 1.91%
90,750
– –
2019 Q4
26 quarters
IMMX icon
10
Immix Biopharma
IMMX
$706M
$10.3M 1.84%
1,000,000
– –
2024 Q1
9 quarters
IDN icon
11
Intellicheck
IDN
$45.4M
$8.43M 1.51%
2,056,343
-17,240
-0.8% -$103K
2019 Q4
26 quarters
SPGI icon
12
S&P Global
SPGI
$120B
$8.15M 1.46%
20,000
– –
2019 Q4
26 quarters
INVE icon
13
INVE Technologies, Inc. Common Stock
INVE
$55.7M
$7.27M 1.3%
2,884,495
– –
2019 Q4
26 quarters
LIQT icon
14
LiqTech
LIQT
$12.7M
$5.84M 1.05%
6,882,239
+3,700,000
+116% +$5.92M
2020 Q1
25 quarters
KZIA icon
15
Kazia Therapeutics
KZIA
$106M
$5.63M 1.01%
400,000
– –
2025 Q4
2 quarters
COCH icon
16
Envoy Medical
COCH
$49.3M
$4.95M 0.89%
6,250,000
– –
2026 Q1
1 quarter
CGEM icon
17
Cullinan Oncology
CGEM
$878M
$4.55M 0.81%
250,000
+150,000
+150% +$2.23M
2026 Q1
1 quarter
WELL icon
18
Welltower
WELL
$167B
$4.54M 0.81%
20,000
– –
2025 Q2
4 quarters
EYPT icon
19
EyePoint Inc
EYPT
$259M
$4.53M 0.81%
316,515
– –
2025 Q2
4 quarters
FLNT icon
20
Fluent
FLNT
$82.2M
$4.26M 0.76%
1,142,857
-285,714
-20% -$831K
2025 Q3
3 quarters
GNLX icon
21
Genelux
GNLX
$105M
$4.16M 0.74%
1,380,666
– –
2025 Q1
5 quarters
PROK icon
22
ProKidney
PROK
$307M
$4.08M 0.73%
2,000,000
– –
2022 Q3
15 quarters
COGT icon
23
Cogent Biosciences
COGT
$4.88B
$3.87M 0.69%
+100,000
New +$3.5M
2026 Q2
0 quarters
QQQ icon
24
Invesco QQQ Trust
QQQ
$488B
$3.42M 0.61%
4,640
– –
2025 Q2
4 quarters
JPM icon
25
JPMorgan Chase
JPM
$890B
$3.34M 0.6%
10,200
-4,800
-32% -$1.49M
2019 Q4
26 quarters
1
2 3 4

Similar funds

NFW
Noble Family Wealth Clearwater, Florida $559M AUM 24.35% 1-Year Est. Return
SCM
Soros Capital Management New York $559M AUM 171.77% 1-Year Est. Return
PHC
Palidye Holdings (Caymans) Grand Cayman, Cayman Islands $559M AUM 1.08% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
BCM
Brasada Capital Management Houston, Texas $558M AUM 21.68% 1-Year Est. Return
FAM
Frontier Asset Management Sheridan, Wyoming $558M AUM 22.41% 1-Year Est. Return
WDG
Wealth Dimensions Group Cincinnati, Ohio $558M AUM 20.63% 1-Year Est. Return
OC
Opal Capital Boca Raton, Florida $560M AUM

Bleichroeder LP's Q2 2026 Portfolio in Review

As of Q2 2026, Bleichroeder LP held 87 positions worth $559M, down 3.4% from $579M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Bleichroeder LP's Q2 2026 filing shows 6 new, 9 increased, 8 reduced and 9 closed positions. Its largest new stake was Cogent Biosciences: 100,000 shares worth $3.87M. The largest sale was Linde, an estimated $4.07M.

By sector, the portfolio is most concentrated in Miscellaneous at 41% of assets, down from 44% a quarter earlier, followed by Industrials and Healthcare.

  • Bleichroeder LP's largest Q2 2026 buy was Cogent Biosciences: 100,000 shares worth $3.87M.
  • Bleichroeder LP added most to LiqTech in Q2 2026, an estimated $5.92M increase.
  • Bleichroeder LP's biggest Q2 2026 reduction was Linde, cutting an estimated $4.07M.
  • Bleichroeder LP fully exited Precision Optics in Q2 2026, selling an estimated $1.19M.
  • Bleichroeder LP's ten largest holdings make up 78% of its $559M portfolio in Q2 2026.
  • Bleichroeder LP opened 6 new positions and closed 9 in Q2 2026.
  • Bleichroeder LP's portfolio value fell 3.4% quarter-over-quarter to $559M.

Based on Bleichroeder LP's 13F filing for Q2 2026, filed 13 Aug 2026.